We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+1.43%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$6.01B
AUM Growth
+$319M
(+5.6%)
Cap. Flow
+$303M
Cap. Flow
% of AUM
5.05%
Top 10 Holdings %
Top 10 Hldgs %
12.12%
Holding
1,131
New
156
Increased
425
Reduced
373
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$34.8M |
| 2 |
Cigna
CI
|
+$31.8M |
| 3 |
UnitedHealth
UNH
|
+$26.4M |
| 4 |
AutoZone
AZO
|
+$24.3M |
| 5 |
Eli Lilly
LLY
|
+$21.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$34.9M |
| 2 |
McKesson
MCK
|
+$25.9M |
| 3 |
XL
XL Group Ltd.
XL
|
+$25.4M |
| 4 |
RHT
Red Hat Inc
RHT
|
+$22M |
| 5 |
AT&T
T
|
+$17.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.15% |
| 2 | Financials | 18.28% |
| 3 | Industrials | 13.53% |
| 4 | Consumer Discretionary | 11.12% |
| 5 | Healthcare | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MACK
826
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $372K | 0.01% |
58,727
+32,799
| +127% | +$271K |
|
827
Amgen
AMGN
$205B
| $370K | 0.01% |
+2,172
| New | +$399K |
|
828
Coherus Oncology
CHRS
$224M
| $370K | 0.01% |
+33,506
| New | +$367K |
|
829
Rocky Brands
RCKY
$307M
| $370K | 0.01% |
17,250
-6,553
| -28% | -$125K |
|
830
Globus Medical
GMED
$10.6B
| $369K | 0.01% |
+7,400
| New | +$348K |
|
|
CALA
831
DELISTED
Calithera Biosciences, Inc
CALA
| $368K | 0.01% |
2,923
+1,995
| +215% | +$311K |
|
832
Crown Holdings
CCK
$13B
| $366K | 0.01% |
7,220
-540
| -7% | -$28.8K |
|
833
Covenant Logistics
CVLG
$1.13B
| $366K | 0.01% |
24,510
-200
| -0.8% | -$2.8K |
|
|
RYZ
834
Ryerson Holding Corp
RYZ
$1.6B
| $366K | 0.01% |
44,962
+24,906
| +124% | +$257K |
|
|
TBNK
835
DELISTED
Territorial Bancorp Inc.
TBNK
| $364K | 0.01% |
12,282
+400
| +3% | +$12.3K |
|
836
Movado Group
MOV
$811M
| $362K | 0.01% |
9,431
| – | – |
|
|
DWCH
837
DELISTED
Datawatch Corp
DWCH
| $353K | 0.01% |
40,776
-27,962
| -41% | -$282K |
|
838
Zevra Therapeutics
ZVRA
$580M
| $350K | 0.01% |
2,765
-609
| -18% | -$58.9K |
|
|
TCON
839
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $348K | 0.01% |
757
+323
| +74% | +$176K |
|
840
Union Pacific
UNP
$181B
| $347K | 0.01% |
2,580
+860
| +50% | +$116K |
|
|
SAGE
841
DELISTED
Sage Therapeutics
SAGE
| $346K | 0.01% |
+2,150
| New | +$365K |
|
|
BDSI
842
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $346K | 0.01% |
153,970
-216,246
| -58% | -$506K |
|
|
UPL
843
DELISTED
Ultra Petroleum Corp. Common Stock
UPL
| $344K | 0.01% |
82,400
-178,000
| -68% | -$1.04M |
|
|
JNP
844
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $340K | 0.01% |
33,501
-5,800
| -15% | -$48.7K |
|
845
Larimar Therapeutics
LRMR
$405M
| $339K | 0.01% |
3,797
-567
| -13% | -$48.1K |
|
846
Ezcorp Inc
EZPW
$1.81B
| $338K | 0.01% |
25,600
+8,500
| +50% | +$109K |
|
847
Halliburton
HAL
$27.3B
| $337K | 0.01% |
7,180
-2,120
| -23% | -$105K |
|
848
Amtech Systems
ASYS
$265M
| $333K | 0.01% |
45,555
-55,578
| -55% | -$500K |
|
|
CAI
849
DELISTED
CAI International, Inc.
CAI
| $333K | 0.01% |
15,640
-10,600
| -40% | -$264K |
|
|
BAS
850
DELISTED
Basis Energy Services, Inc.
BAS
| $332K | 0.01% |
23,000
+11,400
| +98% | +$221K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q1 2018 Portfolio in Review
As of Q1 2018, Jacobs Levy Equity Management held 1,131 positions worth $6.01B, up 5.6% from $5.69B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jacobs Levy Equity Management deployed $303M of net new capital in Q1 2018, opening 156 new positions and adding to 425 existing holdings. Its largest new stake was Cigna: 163,820 shares worth $27.5M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 19% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was ExxonMobil, an estimated $34.9M trimmed.
- Jacobs Levy Equity Management's largest Q1 2018 buy was Cigna: 163,820 shares worth $27.5M.
- Jacobs Levy Equity Management added most to Microsoft in Q1 2018, an estimated $34.8M increase.
- Jacobs Levy Equity Management's biggest Q1 2018 reduction was ExxonMobil, cutting an estimated $34.9M.
- Jacobs Levy Equity Management fully exited XL Group Ltd. in Q1 2018, selling an estimated $25.4M.
- Jacobs Levy Equity Management's ten largest holdings make up 12% of its $6.01B portfolio in Q1 2018.
- Jacobs Levy Equity Management opened 156 new positions and closed 143 in Q1 2018.
- Jacobs Levy Equity Management's portfolio value rose 5.6% quarter-over-quarter to $6.01B.
Based on Jacobs Levy Equity Management's 13F filing for Q1 2018, filed 15 May 2018.